|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0006826,
umls-concept:C0008976,
umls-concept:C0013216,
umls-concept:C0017262,
umls-concept:C0029246,
umls-concept:C0035168,
umls-concept:C0081527,
umls-concept:C0087111,
umls-concept:C0185117,
umls-concept:C0205618,
umls-concept:C0239307,
umls-concept:C0681842,
umls-concept:C1274040,
umls-concept:C1335110,
umls-concept:C2911684
|
|
pubmed:issue |
13
|
|
pubmed:dateCreated |
2011-6-21
|
|
pubmed:abstractText |
Although it has been demonstrated that the neuronal intermediate filament alpha-internexin (INA) is closely related to 1p19q codeletion in gliomas, its prognostic and predictive value has not yet been confirmed in a prospective trial. The authors of this report assessed the prognostic significance of INA expression and its correlation with relevant clinical and molecular characteristics in the prospective, randomized European Organization for Research and Treatment of Cancer (EORTC) 26951 trial of adjuvant procarbazine, lomustine, and vincristine (PCV) in patients with anaplastic oligodendroglial tumors (AOTs).
|
|
pubmed:grant |
http://linkedlifedata.com/resource/pubmed/grant/5U10 CA011488-30,
http://linkedlifedata.com/resource/pubmed/grant/5U10 CA011488-31,
http://linkedlifedata.com/resource/pubmed/grant/5U10 CA011488-32,
http://linkedlifedata.com/resource/pubmed/grant/5U10 CA011488-33,
http://linkedlifedata.com/resource/pubmed/grant/5U10 CA011488-34,
http://linkedlifedata.com/resource/pubmed/grant/5U10 CA011488-35,
http://linkedlifedata.com/resource/pubmed/grant/5U10 CA011488-36,
http://linkedlifedata.com/resource/pubmed/grant/5U10 CA011488-37,
http://linkedlifedata.com/resource/pubmed/grant/5U10 CA011488-38,
http://linkedlifedata.com/resource/pubmed/grant/5U10 CA011488-39,
http://linkedlifedata.com/resource/pubmed/grant/5U10 CA011488-40,
http://linkedlifedata.com/resource/pubmed/grant/5U10 CA11488-26,
http://linkedlifedata.com/resource/pubmed/grant/5U10 CA11488-27,
http://linkedlifedata.com/resource/pubmed/grant/5U10 CA11488-28,
http://linkedlifedata.com/resource/pubmed/grant/5U10 CA11488-29
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/DNA Modification Methylases,
http://linkedlifedata.com/resource/pubmed/chemical/DNA Repair Enzymes,
http://linkedlifedata.com/resource/pubmed/chemical/Intermediate Filament Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Isocitrate Dehydrogenase,
http://linkedlifedata.com/resource/pubmed/chemical/Lomustine,
http://linkedlifedata.com/resource/pubmed/chemical/MGMT protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Procarbazine,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Suppressor Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Vincristine,
http://linkedlifedata.com/resource/pubmed/chemical/alpha-internexin
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
1097-0142
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Copyright © 2011 American Cancer Society.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
1
|
|
pubmed:volume |
117
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
3014-26
|
|
pubmed:meshHeading |
pubmed-meshheading:21246521-Age Factors,
pubmed-meshheading:21246521-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:21246521-Astrocytoma,
pubmed-meshheading:21246521-Brain Neoplasms,
pubmed-meshheading:21246521-Combined Modality Therapy,
pubmed-meshheading:21246521-DNA Modification Methylases,
pubmed-meshheading:21246521-DNA Repair Enzymes,
pubmed-meshheading:21246521-Disease-Free Survival,
pubmed-meshheading:21246521-Female,
pubmed-meshheading:21246521-Humans,
pubmed-meshheading:21246521-Intermediate Filament Proteins,
pubmed-meshheading:21246521-Isocitrate Dehydrogenase,
pubmed-meshheading:21246521-Lomustine,
pubmed-meshheading:21246521-Male,
pubmed-meshheading:21246521-Oligodendroglioma,
pubmed-meshheading:21246521-Procarbazine,
pubmed-meshheading:21246521-Prognosis,
pubmed-meshheading:21246521-Proportional Hazards Models,
pubmed-meshheading:21246521-Sequence Deletion,
pubmed-meshheading:21246521-Treatment Outcome,
pubmed-meshheading:21246521-Tumor Suppressor Proteins,
pubmed-meshheading:21246521-Vincristine
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Alpha-internexin expression predicts outcome in anaplastic oligodendroglial tumors and may positively impact the efficacy of chemotherapy: European organization for research and treatment of cancer trial 26951.
|
|
pubmed:affiliation |
Mixed Research Unit, UMR 975, INSERM, National Institute of Health and Medical Research-Pierre and Marie Curie University, Pitie-Salpetriere Group Hospital, Paris, France.
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, N.I.H., Extramural
|
